The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis

Basit Öğe Kaydı
dc.contributor.authorYücel, Neşe
dc.contributor.authorBaşkent, Erdem
dc.contributor.authorBalcı, Burçin Karamustafaoğlu
dc.contributor.authorGöynümer, Gökhan
dc.date.accessioned2020-04-30T23:33:56Z
dc.date.available2020-04-30T23:33:56Z
dc.date.issued2018
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionBalci, Burcin Karamustafaoglu/0000-0001-5196-4502en_US
dc.descriptionWOS: 000446978700018en_US
dc.descriptionPubMed: 29359457en_US
dc.description.abstractBackground and aimsThe aim of this study was to investigate the effectiveness of a levonorgestrel-releasing intrauterine device (LNG-IUS) in the symptomatic relief of pain in women with endometriosis and additionally, to assess the changes in women's life quality and serum cancer antigen (CA) 125 levels. Materials and methodsAll women who had an LNG-IUS inserted for the treatment of dysmenorrhea, chronic pelvic pain or both for more than six months over a two-year period were included in the study. Each woman was asked to complete questionnaires of the Short Form-36 and visual analogue scales (VAS) in the first visit and the third, sixth, ninth and twelfth months after the LNG-IUS insertion. CA 125 levels were measured at each visit. ResultsForty-five women were included in the study. At the end of 12months, mean dysmenorrhoea VAS score decreased from 6.13 to 2.88, mean dsyspareunia VAS score from 6.04 to 2.61 and CA 125 level from 50.67 to 22.45. Endometriomas reduced in size in six women (mean size decreased from 31 to 20mm) and disappeared in three. ConclusionsSeveral favourable outcomes were found following LNG-IUS insertion: (i) dyspareunia and dysmenorrhoea were clearly reduced; (ii) the size of endometriomas were decreased; (iii) CA 125 levels significantly decreased; (iv) a few women experienced the typical systemic adverse effects of progestogens; however, LNG-IUS-related adverse events were generally tolerable and the discontinuation rate was as low as 6.66% (3/45).en_US
dc.identifier.doi10.1111/ajo.12773en_US
dc.identifier.endpage563en_US
dc.identifier.issn0004-8666
dc.identifier.issn1479-828X
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage560en_US
dc.identifier.urihttps://doi.org/10.1111/ajo.12773
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5072
dc.identifier.volume58en_US
dc.identifier.wosWOS:000446978700018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofAustralian & New Zealand Journal Of Obstetrics & Gynaecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCA 125en_US
dc.subjectcontraceptionen_US
dc.subjectendometriosisen_US
dc.subjectlevonorgestrel-releasing intrauterine deviceen_US
dc.subjectlife qualityen_US
dc.subjectMirenaen_US
dc.titleThe levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5072.pdf
Boyut:
160 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu